<DOC>
	<DOCNO>NCT00633360</DOCNO>
	<brief_summary>To determine augmentation oral-contraceptive pill contain drospirenone ethinyl estradiol effective placebo treatment premenstrual breakthrough depression .</brief_summary>
	<brief_title>The Oral Contraceptive Pill Premenstrual Worsening Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Premenstrual Syndrome</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Inclusion criterion 1 . Women nonsmoker age 1845 year ( smoker 1834 year ) ; 2 . Regular menstrual cycle ( 2634 day length , predictable within 7 day ) past 6 month ; 3 . Determination antidepressant medication initiate treatment unipolar major depression , minor depression ( depression , otherwise specify ) , dysthymia . Major depression dysthymia evaluate administration MiniInternational Neuropsychiatric Interview ( MINI ) . Minor depression evaluate administration Structured Clinical Interview DiagnosisIV ( SCID ) 10 section J.3 . 4 . Use antidepressant least 3 month treatment depressive disorder , stable dose least 2 month . It acceptable one psychiatric medication long one antidepressant . 5 . Expected continued use antidepressant dose duration study ; 6 . 30 % increase midfollicular phase Montgomery√Ösberg Depression Rating Scale ( MADRS ) score lateluteal phase MADRS require eligibility track phase study assess prospectively 1 menstrual cycle . 7 . Normal pelvic exam PAP smear past 12 month ; 8 . Normal TSH screen thyroid medication , must stable dose 2 month great , normal TSH screen ; 9 . Negative serum HCG baseline , negative urine HCG visit 3 5 ; 10 . Normal potassium ( K ) level screen ; 11 . Willingness use barrier contraceptive method study , sexually active ; 12 . Good general health . 1 . Amenorrhea irregular menstrual period ( define unable predict within 7 day ) past 6 month 2 . Pregnancy breastfeeding ( serum HCG test administer baseline study visit , urine HCG visit 3 5 ) 3 . Current cigarette smoking woman older 34 year 4 . Presence follow psychiatric substance use disorder , base administration MINI baseline study visit : Any history mania hypomania suggest bipolar disorder Any lifetime history psychotic disorder 5 . Depression deem physician investigator severe treat study 6 . Use benzodiazepine antipsychotic target premenstrual symptom 7 . Lutealphase dose adjustment antidepressant . Use hormone release IUD ( intrauterine device ) 8 . Use OCP systemic hormonal therapy ( oral , transdermal injection preparation androgen , estrogen , progestin ) past 2 month ; 9 . Any contraindication previous adverse event OCP therapy ; 10 . Current use ketoconazole , rifampin , carbamazepine , topiramate , oxcarbazepine , modafinil , phenytoin , phenobarbital ( interaction hormonal therapy ) . 11 . Current use potassiumsparing agent , potassiumsparing diuretic ( e.g. , spironolactone ) , ACE inhibitor , angiotensinII receptor antagonist , heparin , aldosterone antagonist , NSAIDS , potassium spar diuretic potassiumsupplements ( risk develop arrhythmia two potassiumelevating agent ) . 12 . Hepatic dysfunction , renal insufficiency , pulmonary , adrenal , metabolic disease ( include elevate serum potassium level , know ) may put subject risk treat study medication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Women</keyword>
	<keyword>PMS</keyword>
	<keyword>Depression</keyword>
</DOC>